静脈血栓塞栓症（VTE）に対するザレルトの特別薬物使用調査

基本情報

NCT ID

NCT02558465

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

2,540

治験依頼者名

Bayer

概要

The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism (PE/DVT), all-cause mortality. This study is a company sponsored, one- arm prospective cohort study with patients to whom Rivaroxaban treatment for VTE (PE/DVT) has been chosen. The study includes a standard observation period (1 year) and an extension survey period (2 years, at the longest).

対象疾患

介入

依頼者（Sponsor）